Clinical trials: Moderate-to-severe Psoriasis
Moderate to Severe Plaque Psoriasis
A Phase 2 Clinical Study of KHK4827
This study is designed to evaluate the efficacy and safety of KHK4827 in subjects with moderate to severe plaque psoriasis in a randomized, double-blind, placebo-controlled, parallel group study.
- Trial name
- NCT01748539
- Testing
- KHK4827
- Where
- Japan
- Volunteers
- 140 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Psoriasis
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to evaluate the efficacy of guselkumab compared with secukinumab for the treatment of participants with moderate to severe plaque-type psoriasis.
- Trial name
- ECLIPSE (NCT03090100)
- Testing
- Guselkumab, Secukinumab
- Where
- 142 sites in United States, Australia and 7 more
- Volunteers
- 1,048 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis
The primary objective of this study is to evaluate the efficacy and safety of ustekinumab (CNTO 1275) in the treatment of patients with moderate to severe plaque psoriasis.
- Trial name
- NCT00307437
- Testing
- Ustekinumab (CNTO 1275) 45 mg, Ustekinumab (CNTO 1275) 90 mg
- Where
- 62 sites in United States, Austria and 5 more
- Volunteers
- 1,230 people
- Sponsor
- Centocor Research & Development, Inc.
Plaque Psoriasis
A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)
The study aims to evaluate the clinical efficacy of oral apremilast 30 mg BID compared with placebo in Chinese participants with moderate to severe PsO
- Trial name
- ESSENCE (NCT06122649)
- Testing
- apremilast
- Where
- 21 sites in China
- Volunteers
- 203 people
- Sponsor
- Amgen
Psoriasis Vulgaris, Plaque Psoriasis
A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis
The aim of this study is to evaluate safety, tolerability, and efficacy of PRCL-02 in moderate to severe chronic plaque psoriasis
- Trial name
- NCT03614078
- Testing
- PRCL-02
- Where
- 16 sites in Canada, Slovakia and 1 more
- Volunteers
- 92 people
- Sponsor
- PRCL Research Inc.
Psoriasis
Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
The primary hypothesis of this trial is that the addition of short courses of clobetasol propionate foam to etanercept monotherapy in subjects with moderate to severe plaque psoriasis will yield greater efficacy compared with…
- Trial name
- NCT01235442
- Testing
- 1=Etanercept, 2=Clobetasol propionate foam
- Volunteers
- 592 people
- Sponsor
- Amgen
Rheumatoid Arthritis, Psoriasis
A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis
The purpose of this study is to investigate experimental medication BMS-986251 taken by mouth in healthy patients and patients with average to very serious Psoriasis (a condition characterized by itchy, dry skin with a scaly…
- Conditions
- Rheumatoid Arthritis, Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Diseases
- Trial name
- NCT03329885
- Testing
- BMS-986251
- Where
- Netherlands
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Psoriasis
The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment
This study aims to see if patient quality of life can be approved after treatment with an injectable medication called ustekinumab for the treatment of generalized psoriasis.
- Trial name
- NCT01511315
- Testing
- Ustekinumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of California, San Francisco
Plaque Psoriasis
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
- Trial name
- NCT06220604
- Testing
- JNJ-77242113, Deucravacitinib
- Where
- 128 sites in United States, Australia and 9 more
- Volunteers
- 731 people
- Sponsor
- Janssen Research & Development, LLC
Moderate to Severe Plaque-type Psoriasis
Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens
This study will assess the safety and efficacy of two different doses and two different dose regimens of subcutaneous secukinumab in patients that have moderate to severe, chronic, plaque-type psoriasis.
- Trial name
- SCULPTURE (NCT01406938)
- Testing
- AIN457 150mg, AIN457 300mg
- Where
- 131 sites in United States, Austria and 14 more
- Volunteers
- 967 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The primary objectives of the study are: To evaluate the safety and tolerability of three dose levels of MT-1303 in subjects with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01987843
- Testing
- MT-1303-Low, MT-1303-Middle, MT-1303-High
- Where
- 52 sites in Bulgaria, Estonia and 6 more
- Volunteers
- 142 people
- Sponsor
- Tanabe Pharma Corporation
Psoriasis
A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis
This is a Phase Ib clinical study of multiple dose escalation of AK111 in subjects with moderate-to-severe plaque psoriasis
- Trial name
- NCT05504317
- Testing
- AK111
- Where
- 2 sites in China
- Volunteers
- 48 people
- Sponsor
- Akeso
Psoriasis
Safety and Efficacy of HPP737 in Adult Patients With Plaque Psoriasis
The goal of this clinical trial is to learn if drug HPP737 works to treat moderate-to-severe plaque psoriasis in adults. It will also learn about the safety of drug HPP737.
- Trial name
- NCT07707141
- Testing
- HPP737 20mg
- Where
- 8 sites in China
- Volunteers
- 123 people
- Sponsor
- Newsoara Biopharma Co., Ltd.
Plaque Psoriasis
A Phase II Clinical Study of AC-201 Tablets in Subjects With Plaque Psoriasis
The purpose of the study is to evaluate the efficacy and safety of AC-201 tablets compared with placebo in subjects with moderate-to-severe plaque psoriasis
- Trial name
- NCT06972888
- Testing
- AC-201
- Where
- China
- Volunteers
- 145 people
- Sponsor
- Accro Bioscience (Suzhou) Limited
Psoriasis
A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to determine the efficacy and safety of the study drug recombinant anti-IL-17A humanized monoclonal antibody in Chinese participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT05604898
- Testing
- Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection
- Where
- 3 sites in China
- Volunteers
- 139 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Psoriasis
APremilast After FumaRic Acid Ester Treatment
Patient treatment preference and treatment satisfaction of physicians and patients comparing fumaric acid ester therapy with subsequent apremilast treatment
- Trial name
- APART (NCT02954081)
- Testing
- Phase I: Fumaric acid esters. Phase II: Apremilast
- Where
- Germany
- Volunteers
- 687 people
- Sponsor
- Amgen
Psoriasis
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01163253
- Testing
- CP-690,550
- Where
- 323 sites in United States, Argentina and 34 more
- Volunteers
- 2,867 people
- Sponsor
- Pfizer
Plaque Psoriasis
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment
The main purpose of this study is to evaluate the efficacy of ixekizumab compared to fumaric acid esters (FAE) and methotrexate (MTX) in participants with moderate-to-severe plaque psoriasis who are naive to systemic treatment.
- Trial name
- NCT02634801
- Testing
- Fumaric Acid Esters, Methotrexate, Ixekizumab
- Where
- 21 sites in Germany
- Volunteers
- 162 people
- Sponsor
- Eli Lilly and Company
Scalp Psoriasis
Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp
The primary objective of this study is to evaluate the safety and efficacy of clobetasol propionate spray versus vehicle spray for the management of moderate to severe plaque psoriasis of the scalp.
- Trial name
- NCT00881868
- Testing
- clobetasol propionate spray 0.05%, Vehicle spray
- Where
- 4 sites in United States
- Volunteers
- 81 people
- Sponsor
- Galderma R&D
Chronic Plaque Psoriasis
A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis
Comparison of two dosing regimens of Alefacept in subjects weighing between 100kg and 150kg with moderate to severe Chronic Plaque Psoriasis
- Trial name
- NCT00674063
- Testing
- alefacept
- Where
- 17 sites in United States, Canada
- Volunteers
- 78 people
- Sponsor
- Astellas Pharma Inc